Trudhesa nasal spray shows efficacy for migraines in phase 3 trial - Healio

DENVER — Trudhesa nasal spray provided pain relief for up to three consecutive migraine attacks in an open-label, 52-week phase 3 trial, researchers said at the American Headache Society annual scientific meeting. Trudhesa (dihydroergotamine mesylate, I…

Source/Disclosures Source: Sacco S. Early prediction of response to INP104 for acute treatment of migraine. Presented at: American Headache Society annual scientific meeting; June 9-12, 2022; Denve… [+2020 chars]

full article...